LT4649B - Stanolio kompozicija ir jos panaudojimas - Google Patents
Stanolio kompozicija ir jos panaudojimas Download PDFInfo
- Publication number
- LT4649B LT4649B LT99-018A LT99018A LT4649B LT 4649 B LT4649 B LT 4649B LT 99018 A LT99018 A LT 99018A LT 4649 B LT4649 B LT 4649B
- Authority
- LT
- Lithuania
- Prior art keywords
- sitostanol
- cholesterol
- stanol
- campestanol
- fatty acid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 96
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 claims abstract description 124
- LGJMUZUPVCAVPU-UHFFFAOYSA-N beta-Sitostanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 LGJMUZUPVCAVPU-UHFFFAOYSA-N 0.000 claims abstract description 123
- LGJMUZUPVCAVPU-JFBKYFIKSA-N Sitostanol Natural products O[C@@H]1C[C@H]2[C@@](C)([C@@H]3[C@@H]([C@H]4[C@@](C)([C@@H]([C@@H](CC[C@H](C(C)C)CC)C)CC4)CC3)CC2)CC1 LGJMUZUPVCAVPU-JFBKYFIKSA-N 0.000 claims abstract description 76
- LGJMUZUPVCAVPU-HRJGVYIJSA-N stigmastanol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]2(C)CC1 LGJMUZUPVCAVPU-HRJGVYIJSA-N 0.000 claims abstract description 71
- VGSSUFQMXBFFTM-UHFFFAOYSA-N (24R)-24-ethyl-5alpha-cholestane-3beta,5,6beta-triol Natural products C1C(O)C2(O)CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CC)C(C)C)C1(C)CC2 VGSSUFQMXBFFTM-UHFFFAOYSA-N 0.000 claims abstract description 67
- ARYTXMNEANMLMU-UHFFFAOYSA-N 24alpha-methylcholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(C)C(C)C)C1(C)CC2 ARYTXMNEANMLMU-UHFFFAOYSA-N 0.000 claims abstract description 54
- ARYTXMNEANMLMU-ATEDBJNTSA-N campestanol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]2(C)CC1 ARYTXMNEANMLMU-ATEDBJNTSA-N 0.000 claims abstract description 54
- 235000013305 food Nutrition 0.000 claims abstract description 22
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 53
- 229930195729 fatty acid Natural products 0.000 claims description 53
- 239000000194 fatty acid Substances 0.000 claims description 53
- -1 fatty acid ester Chemical class 0.000 claims description 51
- 235000012000 cholesterol Nutrition 0.000 claims description 44
- NJKOMDUNNDKEAI-UHFFFAOYSA-N beta-sitosterol Natural products CCC(CCC(C)C1CCC2(C)C3CC=C4CC(O)CCC4C3CCC12C)C(C)C NJKOMDUNNDKEAI-UHFFFAOYSA-N 0.000 claims description 40
- KZJWDPNRJALLNS-VJSFXXLFSA-N sitosterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](CC)C(C)C)[C@@]1(C)CC2 KZJWDPNRJALLNS-VJSFXXLFSA-N 0.000 claims description 40
- 229950005143 sitosterol Drugs 0.000 claims description 40
- SGNBVLSWZMBQTH-PODYLUTMSA-N campesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@@H](C)C(C)C)[C@@]1(C)CC2 SGNBVLSWZMBQTH-PODYLUTMSA-N 0.000 claims description 38
- SGNBVLSWZMBQTH-FGAXOLDCSA-N Campesterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 SGNBVLSWZMBQTH-FGAXOLDCSA-N 0.000 claims description 37
- BTEISVKTSQLKST-UHFFFAOYSA-N Haliclonasterol Natural products CC(C=CC(C)C(C)(C)C)C1CCC2C3=CC=C4CC(O)CCC4(C)C3CCC12C BTEISVKTSQLKST-UHFFFAOYSA-N 0.000 claims description 37
- 235000000431 campesterol Nutrition 0.000 claims description 37
- NLQLSVXGSXCXFE-UHFFFAOYSA-N sitosterol Natural products CC=C(/CCC(C)C1CC2C3=CCC4C(C)C(O)CCC4(C)C3CCC2(C)C1)C(C)C NLQLSVXGSXCXFE-UHFFFAOYSA-N 0.000 claims description 35
- KZJWDPNRJALLNS-VPUBHVLGSA-N (-)-beta-Sitosterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@@](C)([C@H]([C@H](CC[C@@H](C(C)C)CC)C)CC4)CC3)CC=2)CC1 KZJWDPNRJALLNS-VPUBHVLGSA-N 0.000 claims description 33
- CSVWWLUMXNHWSU-UHFFFAOYSA-N (22E)-(24xi)-24-ethyl-5alpha-cholest-22-en-3beta-ol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(CC)C(C)C)C1(C)CC2 CSVWWLUMXNHWSU-UHFFFAOYSA-N 0.000 claims description 33
- KLEXDBGYSOIREE-UHFFFAOYSA-N 24xi-n-propylcholesterol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)CCC(CCC)C(C)C)C1(C)CC2 KLEXDBGYSOIREE-UHFFFAOYSA-N 0.000 claims description 33
- LPZCCMIISIBREI-MTFRKTCUSA-N Citrostadienol Natural products CC=C(CC[C@@H](C)[C@H]1CC[C@H]2C3=CC[C@H]4[C@H](C)[C@@H](O)CC[C@]4(C)[C@H]3CC[C@]12C)C(C)C LPZCCMIISIBREI-MTFRKTCUSA-N 0.000 claims description 33
- ARVGMISWLZPBCH-UHFFFAOYSA-N Dehydro-beta-sitosterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)CCC(CC)C(C)C)CCC33)C)C3=CC=C21 ARVGMISWLZPBCH-UHFFFAOYSA-N 0.000 claims description 33
- MJVXAPPOFPTTCA-UHFFFAOYSA-N beta-Sistosterol Natural products CCC(CCC(C)C1CCC2C3CC=C4C(C)C(O)CCC4(C)C3CCC12C)C(C)C MJVXAPPOFPTTCA-UHFFFAOYSA-N 0.000 claims description 33
- 235000015500 sitosterol Nutrition 0.000 claims description 33
- 210000002966 serum Anatomy 0.000 claims description 29
- 235000005911 diet Nutrition 0.000 claims description 27
- 150000002148 esters Chemical class 0.000 claims description 26
- 230000037213 diet Effects 0.000 claims description 15
- 230000000378 dietary effect Effects 0.000 claims description 12
- 150000004665 fatty acids Chemical class 0.000 claims description 8
- 239000003529 anticholesteremic agent Substances 0.000 claims description 3
- 229940127226 anticholesterol agent Drugs 0.000 claims description 3
- 235000015097 nutrients Nutrition 0.000 claims 3
- 239000003925 fat Substances 0.000 abstract description 20
- 239000003921 oil Substances 0.000 abstract description 12
- 238000005886 esterification reaction Methods 0.000 abstract description 10
- 230000032050 esterification Effects 0.000 abstract description 7
- 229930182558 Sterol Natural products 0.000 description 70
- 235000003702 sterols Nutrition 0.000 description 70
- 150000003432 sterols Chemical class 0.000 description 66
- 235000002378 plant sterols Nutrition 0.000 description 44
- 235000013310 margarine Nutrition 0.000 description 35
- 239000003264 margarine Substances 0.000 description 28
- 230000000694 effects Effects 0.000 description 26
- 238000000034 method Methods 0.000 description 24
- 239000003784 tall oil Substances 0.000 description 23
- 235000015112 vegetable and seed oil Nutrition 0.000 description 20
- 239000008158 vegetable oil Substances 0.000 description 20
- 238000010521 absorption reaction Methods 0.000 description 19
- 150000002632 lipids Chemical class 0.000 description 19
- 241000282414 Homo sapiens Species 0.000 description 18
- 229920006395 saturated elastomer Polymers 0.000 description 18
- 235000019197 fats Nutrition 0.000 description 17
- 230000000871 hypocholesterolemic effect Effects 0.000 description 14
- 201000001320 Atherosclerosis Diseases 0.000 description 13
- 230000031891 intestinal absorption Effects 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 238000012360 testing method Methods 0.000 description 11
- 239000003054 catalyst Substances 0.000 description 10
- 238000005984 hydrogenation reaction Methods 0.000 description 10
- 235000019198 oils Nutrition 0.000 description 10
- 230000001906 cholesterol absorption Effects 0.000 description 9
- 238000002360 preparation method Methods 0.000 description 9
- OILXMJHPFNGGTO-UHFFFAOYSA-N (22E)-(24xi)-24-methylcholesta-5,22-dien-3beta-ol Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)C=CC(C)C(C)C)C1(C)CC2 OILXMJHPFNGGTO-UHFFFAOYSA-N 0.000 description 8
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 8
- 241000196324 Embryophyta Species 0.000 description 8
- 230000000260 hypercholesteremic effect Effects 0.000 description 8
- 230000004060 metabolic process Effects 0.000 description 8
- 108010028554 LDL Cholesterol Proteins 0.000 description 7
- 238000008214 LDL Cholesterol Methods 0.000 description 7
- 230000008901 benefit Effects 0.000 description 7
- 229940076810 beta sitosterol Drugs 0.000 description 7
- 238000006243 chemical reaction Methods 0.000 description 7
- 230000008604 lipoprotein metabolism Effects 0.000 description 7
- 238000004519 manufacturing process Methods 0.000 description 7
- 229940068065 phytosterols Drugs 0.000 description 7
- 230000009467 reduction Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 7
- OQMZNAMGEHIHNN-UHFFFAOYSA-N 7-Dehydrostigmasterol Natural products C1C(O)CCC2(C)C(CCC3(C(C(C)C=CC(CC)C(C)C)CCC33)C)C3=CC=C21 OQMZNAMGEHIHNN-UHFFFAOYSA-N 0.000 description 6
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 6
- 208000035150 Hypercholesterolemia Diseases 0.000 description 6
- HZYXFRGVBOPPNZ-UHFFFAOYSA-N UNPD88870 Natural products C1C=C2CC(O)CCC2(C)C2C1C1CCC(C(C)=CCC(CC)C(C)C)C1(C)CC2 HZYXFRGVBOPPNZ-UHFFFAOYSA-N 0.000 description 6
- 210000004369 blood Anatomy 0.000 description 6
- 239000008280 blood Substances 0.000 description 6
- 239000003795 chemical substances by application Substances 0.000 description 6
- 239000008157 edible vegetable oil Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 239000000047 product Substances 0.000 description 6
- HCXVJBMSMIARIN-PHZDYDNGSA-N stigmasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@@H](CC)C(C)C)[C@@]1(C)CC2 HCXVJBMSMIARIN-PHZDYDNGSA-N 0.000 description 6
- 235000016831 stigmasterol Nutrition 0.000 description 6
- 229940032091 stigmasterol Drugs 0.000 description 6
- BFDNMXAIBMJLBB-UHFFFAOYSA-N stigmasterol Natural products CCC(C=CC(C)C1CCCC2C3CC=C4CC(O)CCC4(C)C3CCC12C)C(C)C BFDNMXAIBMJLBB-UHFFFAOYSA-N 0.000 description 6
- 239000003153 chemical reaction reagent Substances 0.000 description 5
- 235000015872 dietary supplement Nutrition 0.000 description 5
- 238000009472 formulation Methods 0.000 description 5
- 239000001257 hydrogen Substances 0.000 description 5
- 229910052739 hydrogen Inorganic materials 0.000 description 5
- 235000014593 oils and fats Nutrition 0.000 description 5
- KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 5
- 239000012071 phase Substances 0.000 description 5
- 239000002904 solvent Substances 0.000 description 5
- HSINOMROUCMIEA-FGVHQWLLSA-N (2s,4r)-4-[(3r,5s,6r,7r,8s,9s,10s,13r,14s,17r)-6-ethyl-3,7-dihydroxy-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-17-yl]-2-methylpentanoic acid Chemical compound C([C@@]12C)C[C@@H](O)C[C@H]1[C@@H](CC)[C@@H](O)[C@@H]1[C@@H]2CC[C@]2(C)[C@@H]([C@H](C)C[C@H](C)C(O)=O)CC[C@H]21 HSINOMROUCMIEA-FGVHQWLLSA-N 0.000 description 4
- 108090001030 Lipoproteins Proteins 0.000 description 4
- 102000004895 Lipoproteins Human genes 0.000 description 4
- 206010063985 Phytosterolaemia Diseases 0.000 description 4
- 208000002227 Sitosterolemia Diseases 0.000 description 4
- 239000003613 bile acid Substances 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 229910052757 nitrogen Inorganic materials 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 238000012552 review Methods 0.000 description 4
- 150000003431 steroids Chemical class 0.000 description 4
- 238000003786 synthesis reaction Methods 0.000 description 4
- 235000013311 vegetables Nutrition 0.000 description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N Benzene Chemical compound C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 description 3
- 244000068988 Glycine max Species 0.000 description 3
- 235000010469 Glycine max Nutrition 0.000 description 3
- 108010023302 HDL Cholesterol Proteins 0.000 description 3
- 208000000563 Hyperlipoproteinemia Type II Diseases 0.000 description 3
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 description 3
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 3
- 241000283973 Oryctolagus cuniculus Species 0.000 description 3
- 206010045261 Type IIa hyperlipidaemia Diseases 0.000 description 3
- 206010048215 Xanthomatosis Diseases 0.000 description 3
- 230000000326 anti-hypercholesterolaemic effect Effects 0.000 description 3
- 210000000941 bile Anatomy 0.000 description 3
- OILXMJHPFNGGTO-ZAUYPBDWSA-N brassicasterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)/C=C/[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZAUYPBDWSA-N 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 201000010099 disease Diseases 0.000 description 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 3
- 201000001386 familial hypercholesterolemia Diseases 0.000 description 3
- 235000021149 fatty food Nutrition 0.000 description 3
- 239000012467 final product Substances 0.000 description 3
- 239000000843 powder Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 235000019640 taste Nutrition 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 3
- 208000001072 type 2 diabetes mellitus Diseases 0.000 description 3
- 235000019871 vegetable fat Nutrition 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- LGJMUZUPVCAVPU-ANOYILKDSA-N (3s,8r,9s,10s,13r,14s,17r)-17-[(2r,5s)-5-ethyl-6-methylheptan-2-yl]-10,13-dimethyl-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-ol Chemical compound C1CC2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CC[C@H](CC)C(C)C)[C@@]1(C)CC2 LGJMUZUPVCAVPU-ANOYILKDSA-N 0.000 description 2
- QYIXCDOBOSTCEI-QCYZZNICSA-N (5alpha)-cholestan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CCCC(C)C)[C@@]2(C)CC1 QYIXCDOBOSTCEI-QCYZZNICSA-N 0.000 description 2
- OILXMJHPFNGGTO-NRHJOKMGSA-N Brassicasterol Natural products O[C@@H]1CC=2[C@@](C)([C@@H]3[C@H]([C@H]4[C@](C)([C@H]([C@@H](/C=C/[C@H](C(C)C)C)C)CC4)CC3)CC=2)CC1 OILXMJHPFNGGTO-NRHJOKMGSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 108010082495 Dietary Plant Proteins Proteins 0.000 description 2
- 241001125671 Eretmochelys imbricata Species 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 240000002129 Malva sylvestris Species 0.000 description 2
- 235000006770 Malva sylvestris Nutrition 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 235000019484 Rapeseed oil Nutrition 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- OILXMJHPFNGGTO-ZRUUVFCLSA-N UNPD197407 Natural products C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)C=C[C@H](C)C(C)C)[C@@]1(C)CC2 OILXMJHPFNGGTO-ZRUUVFCLSA-N 0.000 description 2
- 240000008042 Zea mays Species 0.000 description 2
- 235000005824 Zea mays ssp. parviglumis Nutrition 0.000 description 2
- 235000002017 Zea mays subsp mays Nutrition 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- QYIXCDOBOSTCEI-UHFFFAOYSA-N alpha-cholestanol Natural products C1CC2CC(O)CCC2(C)C2C1C1CCC(C(C)CCCC(C)C)C1(C)CC2 QYIXCDOBOSTCEI-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000012298 atmosphere Substances 0.000 description 2
- 239000003833 bile salt Substances 0.000 description 2
- 238000004061 bleaching Methods 0.000 description 2
- 235000004420 brassicasterol Nutrition 0.000 description 2
- 239000006227 byproduct Substances 0.000 description 2
- 238000003965 capillary gas chromatography Methods 0.000 description 2
- PFKFTWBEEFSNDU-UHFFFAOYSA-N carbonyldiimidazole Chemical compound C1=CN=CN1C(=O)N1C=CN=C1 PFKFTWBEEFSNDU-UHFFFAOYSA-N 0.000 description 2
- 235000013351 cheese Nutrition 0.000 description 2
- 230000008094 contradictory effect Effects 0.000 description 2
- 239000008162 cooking oil Substances 0.000 description 2
- 235000005822 corn Nutrition 0.000 description 2
- 208000029078 coronary artery disease Diseases 0.000 description 2
- 238000013461 design Methods 0.000 description 2
- 239000002270 dispersing agent Substances 0.000 description 2
- 230000029142 excretion Effects 0.000 description 2
- 235000019387 fatty acid methyl ester Nutrition 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 229930182478 glucoside Natural products 0.000 description 2
- 150000008131 glucosides Chemical class 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000001727 in vivo Methods 0.000 description 2
- 230000033227 intestinal cholesterol absorption Effects 0.000 description 2
- 210000000936 intestine Anatomy 0.000 description 2
- 230000001926 lymphatic effect Effects 0.000 description 2
- 235000021073 macronutrients Nutrition 0.000 description 2
- 239000000693 micelle Substances 0.000 description 2
- VLTRZXGMWDSKGL-UHFFFAOYSA-N perchloric acid Chemical compound OCl(=O)(=O)=O VLTRZXGMWDSKGL-UHFFFAOYSA-N 0.000 description 2
- 230000000704 physical effect Effects 0.000 description 2
- 238000012545 processing Methods 0.000 description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 2
- 238000000926 separation method Methods 0.000 description 2
- 229940033331 soy sterol Drugs 0.000 description 2
- 150000003626 triacylglycerols Chemical class 0.000 description 2
- VEUMANXWQDHAJV-UHFFFAOYSA-N 2-[2-[(2-hydroxyphenyl)methylideneamino]ethyliminomethyl]phenol Chemical compound OC1=CC=CC=C1C=NCCN=CC1=CC=CC=C1O VEUMANXWQDHAJV-UHFFFAOYSA-N 0.000 description 1
- AMOGMTLMADGEOQ-UHFFFAOYSA-N 8-tert-butyl-6,9,12,17-tetrahydroxy-16-methyl-2,4,14,19-tetraoxahexacyclo[8.7.2.0^{1,11}.0^{3,7}.0^{7,11}.0^{13,17}]nonadecane-5,15,18-trione Chemical compound O1C2OC(=O)C(O)C32C24C(O)C5OC(=O)C(C)C5(O)C21C(=O)OC4C(O)C3C(C)(C)C AMOGMTLMADGEOQ-UHFFFAOYSA-N 0.000 description 1
- 101150037123 APOE gene Proteins 0.000 description 1
- RZVAJINKPMORJF-UHFFFAOYSA-N Acetaminophen Chemical compound CC(=O)NC1=CC=C(O)C=C1 RZVAJINKPMORJF-UHFFFAOYSA-N 0.000 description 1
- 102100029470 Apolipoprotein E Human genes 0.000 description 1
- 101710095339 Apolipoprotein E Proteins 0.000 description 1
- 108010083590 Apoproteins Proteins 0.000 description 1
- 102000006410 Apoproteins Human genes 0.000 description 1
- 235000011293 Brassica napus Nutrition 0.000 description 1
- 240000002791 Brassica napus Species 0.000 description 1
- 101100216294 Danio rerio apoeb gene Proteins 0.000 description 1
- 208000032928 Dyslipidaemia Diseases 0.000 description 1
- 206010014476 Elevated cholesterol Diseases 0.000 description 1
- 108010007622 LDL Lipoproteins Proteins 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 241000209056 Secale Species 0.000 description 1
- 235000007238 Secale cereale Nutrition 0.000 description 1
- 235000019714 Triticale Nutrition 0.000 description 1
- 235000021307 Triticum Nutrition 0.000 description 1
- 244000098338 Triticum aestivum Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000009471 action Effects 0.000 description 1
- 239000000654 additive Substances 0.000 description 1
- 230000000996 additive effect Effects 0.000 description 1
- OENHQHLEOONYIE-UKMVMLAPSA-N all-trans beta-carotene Natural products CC=1CCCC(C)(C)C=1/C=C/C(/C)=C/C=C/C(/C)=C/C=C/C=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C OENHQHLEOONYIE-UKMVMLAPSA-N 0.000 description 1
- XAGFODPZIPBFFR-UHFFFAOYSA-N aluminium Chemical compound [Al] XAGFODPZIPBFFR-UHFFFAOYSA-N 0.000 description 1
- 229910052782 aluminium Inorganic materials 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 239000010775 animal oil Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 235000019568 aromas Nutrition 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 235000013734 beta-carotene Nutrition 0.000 description 1
- TUPZEYHYWIEDIH-WAIFQNFQSA-N beta-carotene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1=C(C)CCCC1(C)C)C=CC=C(/C)C=CC2=CCCCC2(C)C TUPZEYHYWIEDIH-WAIFQNFQSA-N 0.000 description 1
- 239000011648 beta-carotene Substances 0.000 description 1
- 229960002747 betacarotene Drugs 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 235000014121 butter Nutrition 0.000 description 1
- 235000013339 cereals Nutrition 0.000 description 1
- 238000004587 chromatography analysis Methods 0.000 description 1
- 230000007012 clinical effect Effects 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000010411 cooking Methods 0.000 description 1
- 239000013078 crystal Substances 0.000 description 1
- GVJHHUAWPYXKBD-UHFFFAOYSA-N d-alpha-tocopherol Natural products OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000004332 deodorization Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 238000010790 dilution Methods 0.000 description 1
- 239000012895 dilution Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 235000013601 eggs Nutrition 0.000 description 1
- 230000008030 elimination Effects 0.000 description 1
- 238000003379 elimination reaction Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 239000010696 ester oil Substances 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- ZYNDJIBBPLNPOW-UHFFFAOYSA-N eurucic acid methyl ester Natural products CCCCCCCCC=CCCCCCCCCCCCC(=O)OC ZYNDJIBBPLNPOW-UHFFFAOYSA-N 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 230000002550 fecal effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 239000011888 foil Substances 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 238000001030 gas--liquid chromatography Methods 0.000 description 1
- 239000000383 hazardous chemical Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000001771 impaired effect Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 238000009884 interesterification Methods 0.000 description 1
- 230000000968 intestinal effect Effects 0.000 description 1
- 238000002386 leaching Methods 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 235000010746 mayonnaise Nutrition 0.000 description 1
- 239000008268 mayonnaise Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 150000004702 methyl esters Chemical class 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000006386 neutralization reaction Methods 0.000 description 1
- 235000016709 nutrition Nutrition 0.000 description 1
- 210000002741 palatine tonsil Anatomy 0.000 description 1
- 229910052763 palladium Inorganic materials 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- LGJMUZUPVCAVPU-GJAZBXDESA-N poriferastan-3beta-ol Chemical compound C([C@@H]1CC2)[C@@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@H](C)CC[C@H](CC)C(C)C)[C@@]2(C)CC1 LGJMUZUPVCAVPU-GJAZBXDESA-N 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 235000012045 salad Nutrition 0.000 description 1
- 235000014438 salad dressings Nutrition 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- QDRKDTQENPPHOJ-UHFFFAOYSA-N sodium ethoxide Chemical compound [Na+].CC[O-] QDRKDTQENPPHOJ-UHFFFAOYSA-N 0.000 description 1
- 230000003381 solubilizing effect Effects 0.000 description 1
- 239000003549 soybean oil Substances 0.000 description 1
- 235000012424 soybean oil Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- 238000004809 thin layer chromatography Methods 0.000 description 1
- 229960001295 tocopherol Drugs 0.000 description 1
- 229930003799 tocopherol Natural products 0.000 description 1
- 235000010384 tocopherol Nutrition 0.000 description 1
- 239000011732 tocopherol Substances 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 239000003053 toxin Substances 0.000 description 1
- 231100000765 toxin Toxicity 0.000 description 1
- 108700012359 toxins Proteins 0.000 description 1
- UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
- 238000005292 vacuum distillation Methods 0.000 description 1
- 241000228158 x Triticosecale Species 0.000 description 1
- GVJHHUAWPYXKBD-IEOSBIPESA-N α-tocopherol Chemical compound OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-IEOSBIPESA-N 0.000 description 1
- OENHQHLEOONYIE-JLTXGRSLSA-N β-Carotene Chemical compound CC=1CCCC(C)(C)C=1\C=C\C(\C)=C\C=C\C(\C)=C\C=C\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C OENHQHLEOONYIE-JLTXGRSLSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
- A23L33/11—Plant sterols or derivatives thereof, e.g. phytosterols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Mycology (AREA)
- Nutrition Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
- Edible Oils And Fats (AREA)
- Saccharide Compounds (AREA)
- Steroid Compounds (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Seasonings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FI963126A FI107015B (fi) | 1996-08-09 | 1996-08-09 | Kasvistanolirasvahappoestereiden seos ja sen käyttö sekä elintarvike |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| LT99018A LT99018A (lt) | 1999-12-27 |
| LT4649B true LT4649B (lt) | 2000-04-25 |
Family
ID=8546469
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| LT99-018A LT4649B (lt) | 1996-08-09 | 1999-02-26 | Stanolio kompozicija ir jos panaudojimas |
Country Status (27)
| Country | Link |
|---|---|
| EP (2) | EP1452180A1 (enExample) |
| JP (3) | JP2000513730A (enExample) |
| KR (1) | KR100440640B1 (enExample) |
| CN (1) | CN1165312C (enExample) |
| AT (1) | ATE266408T1 (enExample) |
| AU (1) | AU734418B2 (enExample) |
| BR (1) | BRPI9612693B8 (enExample) |
| CA (1) | CA2262600C (enExample) |
| CZ (1) | CZ290903B6 (enExample) |
| DE (1) | DE69632481T3 (enExample) |
| DK (1) | DK0871451T4 (enExample) |
| EE (1) | EE03747B1 (enExample) |
| ES (1) | ES2220986T5 (enExample) |
| FI (1) | FI107015B (enExample) |
| HU (1) | HU228301B1 (enExample) |
| IL (1) | IL128458A (enExample) |
| LT (1) | LT4649B (enExample) |
| LV (1) | LV12307B (enExample) |
| NO (1) | NO326262B1 (enExample) |
| NZ (1) | NZ334496A (enExample) |
| PL (1) | PL331515A1 (enExample) |
| PT (1) | PT871451E (enExample) |
| SI (1) | SI9620141B (enExample) |
| SK (1) | SK285849B6 (enExample) |
| UA (1) | UA66763C2 (enExample) |
| WO (1) | WO1998006405A1 (enExample) |
| ZA (1) | ZA967616B (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU664827B2 (en) | 1991-05-03 | 1995-12-07 | Raisio Benecol Ltd. | A substance for lowering high cholesterol level in serum and a method for preparing the same |
| US6544973B1 (en) | 1995-07-28 | 2003-04-08 | Raisio Benecol Ltd. | Substance for lowering high cholesterol level in serum and methods for preparing and using the same |
| US6642268B2 (en) | 1994-09-13 | 2003-11-04 | G.D. Searle & Co. | Combination therapy employing ileal bile acid transport inhibiting benzothipines and HMG Co-A reductase inhibitors |
| US6262277B1 (en) | 1994-09-13 | 2001-07-17 | G.D. Searle And Company | Intermediates and processes for the preparation of benzothiepines having activity as inhibitors of ileal bile acid transport and taurocholate uptake |
| US20030104035A1 (en) | 1996-08-09 | 2003-06-05 | Raisio Benecol Ltd. | Stanol composition and the use thereof |
| US6929816B2 (en) | 1998-01-21 | 2005-08-16 | Raisio Benecol Ltd. | Fat compositions for use in food |
| UA69378C2 (uk) * | 1996-11-04 | 2004-09-15 | Райзіо Бенекол Лтд. | Текстуруюча композиція, текстуруючий агент, харчовий продукт, жирові суміші та способи їх одержання |
| FI107538B (fi) * | 1997-02-26 | 2001-08-31 | Raisio Benecol Oy | Menetelmä stanoliesterien valmistamiseksi |
| ES2222553T3 (es) * | 1997-08-22 | 2005-02-01 | Unilever N.V. | Producto alimenticio a base de grasa que comprende esteroles. |
| DE69826592T2 (de) * | 1997-08-22 | 2006-02-23 | Unilever N.V. | Verfahren zur Herstellung von Stanolestern |
| ES2272882T3 (es) | 1997-08-22 | 2007-05-01 | Unilever N.V. | Composciones que comprenden estanol. |
| EP0897971B1 (en) * | 1997-08-22 | 2004-11-03 | Unilever N.V. | Stanol ester composition |
| EP1440619B1 (en) * | 1997-08-22 | 2006-11-02 | Unilever N.V. | Fat based food products comprising sterols |
| ES2231940T3 (es) * | 1997-08-22 | 2005-05-16 | Unilever N.V. | Composicion de esteres de estanol. |
| FI974648A7 (fi) | 1997-09-09 | 1999-05-06 | Raisio Benecol Oy | Hydroksihappo-, maitohappo- ja hydroksialkanoaattiesterit ja niiden käyttö |
| EP1066313A1 (de) * | 1998-03-23 | 2001-01-10 | Cognis Deutschland GmbH | Verfahren zur herstellung von stanolen |
| US6025348A (en) * | 1998-04-30 | 2000-02-15 | Kao Corporation | Oil and fat composition containing phytosterol |
| US6123978A (en) | 1998-08-31 | 2000-09-26 | Mcneil-Ppc, Inc. | Stable salad dressings |
| US6277431B1 (en) * | 1998-10-14 | 2001-08-21 | Redeem, Inc. | Anticholesterolemic edible oil |
| FI115527B (fi) * | 1998-10-16 | 2005-05-31 | Upm Kymmene Oyj | Kasvisterolijohdannaisten käyttö ja niitä sisältäviä tuotteita |
| ID24148A (id) * | 1998-11-26 | 2000-07-13 | Hoffmann La Roche | Turunan-turunan fitostfrol dan/atau fitostanol |
| US6113972A (en) * | 1998-12-03 | 2000-09-05 | Monsanto Co. | Phytosterol protein complex |
| EP1340508A1 (en) | 1998-12-23 | 2003-09-03 | G.D. Searle LLC. | Combinations of cholesteryl ester transfer protein inhibitors and nicotinic acid derivatives for cardiovascular indications |
| AU3228100A (en) | 1999-02-10 | 2000-08-29 | Eastman Chemical Company | Corn fiber for the production of advanced chemicals and materials |
| BR0010597A (pt) | 1999-04-12 | 2002-02-13 | Monsanto Technology Llc | Plantas transgênicas contendo nìveis alterados de compostos esterol e tocoferóis |
| FI991533L (fi) * | 1999-07-05 | 2001-01-06 | Sohkar Oy | Menetelmä orgaanisten aineiden käsittelemiseksi |
| US6998501B1 (en) | 1999-08-30 | 2006-02-14 | Ocean Nutrition Canada Limited | Nutritional supplement for lowering serum triglyceride and cholesterol levels |
| US7157619B1 (en) | 1999-08-30 | 2007-01-02 | Monsanto Technology, L.L.C. | Plant sterol acyltransferases |
| AU6813700A (en) * | 1999-08-30 | 2001-03-26 | Ocean Nutrition Canada Ltd. | A nutritional supplement for lowering serum triglyceride and cholesterol levels |
| US6677327B1 (en) | 1999-11-24 | 2004-01-13 | Archer-Daniels-Midland Company | Phytosterol and phytostanol compositions |
| ATE323714T1 (de) * | 2000-01-21 | 2006-05-15 | Forbes Medi Tech Inc | Krystalline zusammensetzungen enthaltend phytosterole und phytostanole oder derivate davon |
| EP1252137A1 (en) | 2000-01-28 | 2002-10-30 | The Procter & Gamble Company | Palatable arginine compounds and uses thereof for cardiovascular health |
| DK1121928T3 (da) * | 2000-01-31 | 2008-03-17 | Haerting S A | Sammensætninger indeholdende phytosterol- og policosanolestere af fedtsyrer til reduktion af niveauet af blodcholesterol og -triglycerider |
| JP4970690B2 (ja) | 2000-04-14 | 2012-07-11 | マース インコーポレーテッド | 血管の健康状態を改善するための組成物および方法 |
| FI20010780A0 (fi) * | 2001-04-12 | 2001-04-12 | Raisio Benecol Oy | Parannetut koostumukset |
| CA2471639A1 (en) | 2002-01-17 | 2003-07-31 | Pharmacia Corporation | Novel alkyl/aryl hydroxy or keto thiepines. |
| US20080182801A1 (en) | 2003-12-22 | 2008-07-31 | Btg International Limited | Core 2 glcnac-t inhibitors |
| GB0513881D0 (en) | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Core 2 GLCNAC-T Inhibitors III |
| GB0329667D0 (en) | 2003-12-22 | 2004-01-28 | King S College London | Core 2 GlcNAc-T inhibitor |
| US8158184B2 (en) | 2004-03-08 | 2012-04-17 | Bunge Oils, Inc. | Structured lipid containing compositions and methods with health and nutrition promoting characteristics |
| GB0513888D0 (en) | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Core 2 GLCNAC-T Inhibitors II |
| GB0513883D0 (en) | 2005-07-06 | 2005-08-10 | Btg Int Ltd | Diagnosis of Atherosclerosis |
| IE20060710A1 (en) * | 2005-09-28 | 2007-07-25 | Alltracel Dev Services Ltd | Use of polyanhydroglucronic acid |
| JP2009521416A (ja) * | 2005-12-20 | 2009-06-04 | フォーブス メディ−テック インコーポレーテッド | 水相中にエステル化されていないフィトステロールを含むエマルジョン |
| US20070148311A1 (en) | 2005-12-22 | 2007-06-28 | Bunge Oils, Inc. | Phytosterol esterification product and method of make same |
| AU2007222697B2 (en) * | 2006-03-08 | 2012-07-05 | Cognis Ip Management Gmbh | Powder containing sterol |
| DE102006041302A1 (de) * | 2006-03-08 | 2007-09-13 | Cognis Ip Management Gmbh | Sterolester mit kurzkettigen Fettsäuren |
| US20080124387A1 (en) | 2006-11-27 | 2008-05-29 | Kapac, Llc | Methods and formulations for enhancing the absorption and decreasing the absorption variability of orally administered drugs, vitamins and nutrients |
| FI123374B (fi) | 2011-03-25 | 2013-03-15 | Ravintoraisio Oy | Uusi syötävä koostumus |
| PL3287014T3 (pl) * | 2016-08-22 | 2020-08-24 | Verbio Vereinigte Bioenergie Ag | Sposób wytwarzania kompozycji fitosteroli-fitostanoli |
| WO2021170873A1 (en) * | 2020-02-27 | 2021-09-02 | Basf Se | Composition for the treatment of (pre)hypercholesterolemia and/or associated morbidities thereto |
| GB202110358D0 (en) * | 2021-07-19 | 2021-09-01 | Meda Pharma S P A | Composition |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU664827B2 (en) * | 1991-05-03 | 1995-12-07 | Raisio Benecol Ltd. | A substance for lowering high cholesterol level in serum and a method for preparing the same |
| US5244887A (en) * | 1992-02-14 | 1993-09-14 | Straub Carl D | Stanols to reduce cholesterol absorption from foods and methods of preparation and use thereof |
-
1996
- 1996-08-09 FI FI963126A patent/FI107015B/fi not_active IP Right Cessation
- 1996-09-02 WO PCT/FI1996/000465 patent/WO1998006405A1/en not_active Ceased
- 1996-09-02 DE DE69632481T patent/DE69632481T3/de not_active Expired - Lifetime
- 1996-09-02 PL PL96331515A patent/PL331515A1/xx unknown
- 1996-09-02 IL IL12845896A patent/IL128458A/en not_active IP Right Cessation
- 1996-09-02 SI SI9620141A patent/SI9620141B/sl active Search and Examination
- 1996-09-02 PT PT96928481T patent/PT871451E/pt unknown
- 1996-09-02 AU AU68230/96A patent/AU734418B2/en not_active Expired
- 1996-09-02 EE EEP199900040A patent/EE03747B1/xx not_active IP Right Cessation
- 1996-09-02 EP EP04011018A patent/EP1452180A1/en not_active Withdrawn
- 1996-09-02 EP EP96928481A patent/EP0871451B2/en not_active Expired - Lifetime
- 1996-09-02 CZ CZ1999346A patent/CZ290903B6/cs not_active IP Right Cessation
- 1996-09-02 NZ NZ334496A patent/NZ334496A/xx not_active IP Right Cessation
- 1996-09-02 JP JP10509427A patent/JP2000513730A/ja not_active Withdrawn
- 1996-09-02 CN CNB961804068A patent/CN1165312C/zh not_active Expired - Lifetime
- 1996-09-02 SK SK112-99A patent/SK285849B6/sk not_active IP Right Cessation
- 1996-09-02 KR KR10-1999-7001057A patent/KR100440640B1/ko not_active Expired - Lifetime
- 1996-09-02 ES ES96928481T patent/ES2220986T5/es not_active Expired - Lifetime
- 1996-09-02 CA CA002262600A patent/CA2262600C/en not_active Expired - Lifetime
- 1996-09-02 HU HU0001020A patent/HU228301B1/hu not_active IP Right Cessation
- 1996-09-02 AT AT96928481T patent/ATE266408T1/de active
- 1996-09-02 DK DK96928481T patent/DK0871451T4/da active
- 1996-09-02 BR BRPI9612693A patent/BRPI9612693B8/pt not_active IP Right Cessation
- 1996-09-02 UA UA99021088A patent/UA66763C2/xx unknown
- 1996-09-10 ZA ZA967616A patent/ZA967616B/xx unknown
-
1999
- 1999-02-05 NO NO19990559A patent/NO326262B1/no not_active IP Right Cessation
- 1999-02-26 LT LT99-018A patent/LT4649B/lt not_active IP Right Cessation
- 1999-03-09 LV LVP-99-41A patent/LV12307B/en unknown
-
2003
- 2003-12-03 JP JP2003405151A patent/JP4554915B2/ja not_active Expired - Fee Related
-
2009
- 2009-02-04 JP JP2009024241A patent/JP2009102421A/ja active Pending
Non-Patent Citations (5)
| Title |
|---|
| B. DAYAL ET AL.: "Identification of 5α-stanols in patients with sitosterolemia and xanthomatosis: stereochemistry of the protonolysis of steroidal organoboranes.", STEROIDS, 1982, pages 233 - 243, XP023429562, DOI: doi:10.1016/0039-128X(82)90036-8 |
| GRETEN H.: "Lipoprotein metabolism", pages: 112 - 118 |
| GRETEN H.: "Lipoprotein metabolism", pages: 119 - 124 |
| LING W H: "Minireview dietary phytosterols: A review of metabolism", LIFE SCIENCES, 1995, pages 195 - 206, XP000995149, DOI: doi:10.1016/0024-3205(95)00263-6 |
| POLLAK OJ: "Effect of plant sterols on serum lipids and atherosclerosis", PHARMAC THER, 1985, pages 117 - 208 |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| LT4649B (lt) | Stanolio kompozicija ir jos panaudojimas | |
| Thompson et al. | History and development of plant sterol and stanol esters for cholesterol-lowering purposes | |
| EP1453386A1 (en) | Prepared foods containing triglyceride-recrystallized non-esterified phytosterols | |
| US8853191B2 (en) | Stanol composition and the use thereof | |
| RU2172629C2 (ru) | Станоловая композиция и ее применение | |
| US20060188635A1 (en) | Food product comprising phytosterols | |
| MXPA99001350A (es) | Composicionde estanol y el uso de la misma | |
| JP2002138295A (ja) | 油脂組成物 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM9A | Lapsed patents |
Effective date: 20130902 |